Fingerprint
Dive into the research topics of 'Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically